Eaton Vance Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $22.8M | Buy |
287,557
+31,459
| +12% | +$2.5M | 0.03% | 408 |
|
|
2022
Q2 | $19M | Buy |
256,098
+146,790
| +134% | +$10.9M | 0.03% | 469 |
|
|
2022
Q1 | $9.83M | Sell |
109,308
-70,383
| -39% | -$6.33M | 0.01% | 696 |
|
|
2021
Q4 | $20.1M | Buy |
179,691
+2,326
| +1% | +$260K | 0.02% | 472 |
|
|
2021
Q3 | $22.2M | Buy |
177,365
+6,736
| +4% | +$844K | 0.03% | 408 |
|
|
2021
Q2 | $23.1M | Sell |
170,629
-1,042
| -0.6% | -$141K | 0.03% | 427 |
|
|
2021
Q1 | $23.3M | Buy |
171,671
+6,451
| +4% | +$875K | 0.03% | 410 |
|
|
2020
Q4 | $23.3M | Sell |
165,220
-36,184
| -18% | -$5.09M | 0.04% | 391 |
|
|
2020
Q3 | $22.4M | Sell |
201,404
-8,951
| -4% | -$997K | 0.04% | 341 |
|
|
2020
Q2 | $23.5M | Sell |
210,355
-13,548
| -6% | -$1.52M | 0.05% | 311 |
|
|
2020
Q1 | $17.3M | Buy |
223,903
+38,911
| +21% | +$3.01M | 0.04% | 316 |
|
|
2019
Q4 | $17.6M | Buy |
184,992
+3,138
| +2% | +$298K | 0.03% | 357 |
|
|
2019
Q3 | $13.9M | Buy |
181,854
+9,281
| +5% | +$708K | 0.03% | 381 |
|
|
2019
Q2 | $15.1M | Buy |
172,573
+11,536
| +7% | +$1.01M | 0.03% | 353 |
|
|
2019
Q1 | $14.6M | Buy |
161,037
+50,111
| +45% | +$4.54M | 0.03% | 340 |
|
|
2018
Q4 | $7.96M | Sell |
110,926
-6,673
| -6% | -$479K | 0.02% | 419 |
|
|
2018
Q3 | $11.3M | Buy |
117,599
+17,469
| +17% | +$1.67M | 0.03% | 390 |
|
|
2018
Q2 | $9.53M | Sell |
100,130
-72,954
| -42% | -$6.94M | 0.02% | 407 |
|
|
2018
Q1 | $15.2M | Buy |
173,084
+98,720
| +133% | +$8.66M | 0.02% | 431 |
|
|
2017
Q4 | $6.31M | Buy |
74,364
+38,685
| +108% | +$3.28M | 0.02% | 469 |
|
|
2017
Q3 | $3.09M | Buy |
35,679
+14,258
| +67% | +$1.23M | 0.01% | 595 |
|
|
2017
Q2 | $1.65M | Buy |
+21,421
| New | +$1.65M | ﹤0.01% | 712 |
|